Major pharmaceutical companies, including Pfizer, Eli Lilly, and Amgen, are competing in the GLP-1 weight loss drug market.

The entities involved

• Pfizer →

  American multinational pharmaceutical and biotechnology corporation

  • MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Sat 18:12
  • PepsiCo, Meta, Toyota, Google, and Pfizer contributed founding council members to the Peerworks initiative led by Zero100.Fri 10:24
• Amgen →

  American multinational biopharmaceutical company

  • Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Sat 18:11
  • Amgen's drug Imdelltra showed positive Phase 3 trial results and is now being combined with Imfinzi in new trials.Sat 18:11
• Eli Lilly and Company →

  American pharmaceutical company

  • Eli Lilly CEO David A. Ricks issued a company statement, coinciding with shares jumping in New York premarket trading.05:25
  • A fund prospectus was filed with the SEC, and Eli Lilly now constitutes about 17% of assets in the Health Care Select Sector SPDR Fund.Sat 21:37

Related events

• Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Jun 10
• BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Oct 22
• AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Jun 8
• Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Sep 23
• Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Jun 18